Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alessandra Araujo Gomes"'
Autor:
Ana Luiza de Melo Rodrigues, Carmem Bonfim, Adriana Seber, Vergilio Antonio Rensi Colturato, Victor Gottardello Zecchin, Samantha Nichele, Liane Esteves Daudt, Juliana Folloni Fernandes, Ana Karine Vieira, Luiz Guilherme Darrigo Junior, Alessandra Araujo Gomes, Leonardo Arcuri, Luana Lenzi, Gledson Luiz Picharski, Raul Correa Ribeiro, Bonald Cavalcante de Figueiredo
Publikováno v:
Cell Transplantation, Vol 29 (2020)
The survival rates of children with high-risk acute myeloid leukemia (AML) treated with hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. The corresponding rate for Brazilian children with AML who undergo HSCT
Externí odkaz:
https://doaj.org/article/4c1b04a9df834c4caef257dc20f028d0
Autor:
Vanderson Rocha, Wanessa Miranda-Silva, Felipe Paiva Fonseca, Alessandra Araujo Gomes, Eduardo Rodrigues Fregnani, Ana Beatriz Mafra
Publikováno v:
International Journal of Paediatric Dentistry. 32:251-263
BACKGROUND Oral mucositis (OM) is an important side effect related to allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it has been associated with a significative reduction of quality of life. A negative impact of this toxicity in
Autor:
Vaneuza Araujo Moreira Funke, Samantha Nichele, Samir Kanaan Nabhan, Adriana Seber, Vergilio A.R. Colturato, Liane Esteves Daudt, Gisele Loth, Elias Hallack Atta, Belinda Pinto Simões, Juliana Folloni Fernandes, José Salvador Rodrigues de Oliveira, Mary E.D. Flowers, Andreza Alice Feitosa Ribeiro, Ana Luiza Melo Rodrigues, Luiz Guilherme Darrigo Junior, Leonardo Javier Arcuri, Rodolfo Calixto, Alessandra Araujo Gomes, Nelson Hamerschlak, Renato Cunha, Vanderson Rocha, Carmem Bonfim, Carlos Eduardo Sá Araújo, Celso Arrais-Rodrigues, Alessandra Aparecida Paz, Ricardo Pasquini
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:2311-2317
Severe aplastic anemia (SAA) is a life-threatening disease that can be cured with allogeneic cell transplantation (HCT). Haploidentical donor transplantation with post-transplantation cyclophosphamide (haplo-PTCy) is an option for patients lacking an
Autor:
Vanderson Rocha, Julia Lopes Garcia, Lisandro Ribeiro, Anders Fasth, Gabriele Zamperlini-Netto, Adriana Koliski, Joanna Trennepohl, Nelson Hamerschlak, Cilmara Kuwahara, Samantha Nichele, Alessandra Araujo Gomes, Carmem Bonfim, Ricardo Pasquini, Adriana Seber, Liane Esteves Daudt, Gisele Loth, Ana Luiza Melo Rodrigues, Juliana Folloni Fernandes, Leonardo Javier Arcuri
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:1923-1929
Allogeneic hematopoietic stem cell transplantation (HCT) can cure primary immunodeficiency diseases (PID). When a HLA-matched donor is not available, a haploidentical family donor may be considered. The use of T cell-replete haploidentical HCT with p
Autor:
Nelson Hamerschlak, Ricardo Pasquini, Alessandra Araujo Gomes, Juliana Folloni Fernandes, Gisele Loth, Fabio Rodrigues Kerbauy, Adriana Seber, Vanderson Rocha, Vergilio A.R. Colturato, Andreza Alice Feitosa Ribeiro, Rita de Cássia Barbosa da Silva Tavares, Lisandro Ribeiro, Victor Zecchin, Magda Carneiro-Sampaio, Liane Esteves Daudt, Luiz Guilherme Darrigo-Junior, Ana Luiza Melo Rodrigues, Samantha Nichele, Adriana Koliski, Luiz Fernando Alves Lima Mantovani, Carmem Bonfim, Beatriz Tavares Costa-Carvalho, Cilmara Kuwahara, Andrew R. Gennery, Anders Fasth, Antonio Condino-Neto, Ana Karine Vieira
Publikováno v:
Journal of Clinical Immunology. 38:917-926
The results of hematopoietic stem cell transplant (HSCT) for primary immunodeficiency diseases (PID) have been improving over time. Unfortunately, developing countries do not experience the same results. This first report of Brazilian experience of H
Autor:
Carmem Bonfim, Liane Esteves Daudt, Alessandra Araujo Gomes, Juliana Folloni Fernandes, Adriana Mello Rodrigues
Publikováno v:
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY. 2:126
Hematopoietic stem cell transplantation (HSCT) has the potential to cure a significant proportion of patients with malignant and nonmalignant diseases. The main rationale for HSCT in inborn errors of metabolism (IEM) is based on correcting the decrea
Autor:
Gabriele Zamperlini Netto, Alessandra Araujo Gomes, Carla Nolasco Monteiro Breviglieri, Natalia Maria Tavares Ferreira Borges
Publikováno v:
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY. 2:125
Hematopoietic stem cell transplantation (HSCT) has the potential to cure a significant proportion of patients with malignant and nonmalignant diseases, but the high doses of chemotherapy and/or radiotherapy included in conditioning regimens affect al
Autor:
Camila Derminio Donadel, Bruno Garcia Pires, Nathália Cristine André, Thalita Cristina Mello Costa, Maristela Delgado Orellana, Sâmia Rigotto Caruso, Adriana Seber, Valéria Cortez Ginani, Alessandra Araújo Gomes, Yana Novis, George Maurício Navarro Barros, Neysimélia Costa Vilella, Gláucia Helena Martinho, Ana Karine Vieira, Andrea Tiemi Kondo, Nelson Hamerschlak, Jayr Schmidt Filho, Erick Menezes Xavier, Juliana Folloni Fernandes, Vanderson Rocha, Dimas Tadeu Covas, Rodrigo Tocantins Calado, Renato Luiz Guerino-Cunha, Gil Cunha De Santis
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 512 (2023)
Background: Steroid-refractory acute graft-vs.-host disease (SR-aGVHD) is a complication of allogeneic hematopoietic stem cell transplantation with a dismal prognosis and for which there is no consensus-based second-line therapy. Ruxolitinib is not e
Externí odkaz:
https://doaj.org/article/8b215d26c9fc4c4399a42057c8f205d3